Alcon (ALC) said Tuesday its Unity vitreoretinal cataract system, or Unity VCS, was approved by Health Canada for use in the country.
The platform combines vitreoretinal and cataract surgical innovations into a single integrated system, the company said.
Alcon said it expects to launch Unity VCS commercially in Canada in early 2026.
Price: 86.73, Change: -0.07, Percent Change: -0.08
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.